NeuroClin Glasgow

What NeuroClin Glasgow does

NeuroClin Glasgow (legal name: NeuroClin) is a privately held neurological research organization headquartered in Scotland, United Kingdom, with operations based in the Glasgow/Motherwell area. Founded in 2003, the company focuses on clinical research into three high-unmet-need neurological conditions: Alzheimer's disease, Parkinson's disease, and depression. It operates as a subsidiary under the control of private equity sponsor N4 Partners, which increased its stake via a seven-figure investment in January 2024. The company currently employs approximately 60 staff, up from a prior 11–50 headcount range, and recently expanded its headquarters to support a newly launched Parkinson's research program alongside its existing Alzheimer's and depression research streams.

The company's core activity is research rather than commercial product development; no named products, modules, APIs, or proprietary technology platforms are disclosed in the available source material, and core technology is recorded as 'Not disclosed'. Its revenue model is described as research funding and investment capital flowing from N4 Partners rather than from product or service sales, with pricing not publicly disclosed. The addressable customer base is positioned as healthcare institutions, medical research organizations, and pharmaceutical companies conducting neurological research, though no named customer relationships, contracts, or case studies are documented. Under the current ownership structure, NeuroClin functions as a PE-controlled research platform, with strategic direction set by CEO Fiona Wood and capital deployment tied to the sponsor's expanded ownership position.

From a go-to-market perspective, NeuroClin operates a sales/research-led model in which its 'distribution' is effectively the production of research outputs (publications, collaborations, and programs) rather than the sale of a discrete product. No marketing channels, partnerships beyond N4 Partners, regulatory certifications, patents, or awards are disclosed. The investment profile is therefore best characterized as a sponsor-backed, pre-commercial neurological research asset with concentrated funding dependency on a single financial sponsor and limited externally verifiable signals of research throughput, IP generation, or pipeline progression.

Name

NeuroClin Glasgow

Legal name

NeuroClin

Website

https://neuroclin.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

NeuroClin Glasgow is a Scotland-based neurological research organization conducting clinical research into Alzheimer's disease, Parkinson's disease, and depression. Owned by private equity firm N4 Partners, it operates from an expanded headquarters with approximately 60 employees.

Ownership category

akta.pro rank

Headquarters

HQ city

Motherwell

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Research Funding: The company operates primarily through research funding and investment capital from N4 Partners. As a neurological research organization, NeuroClin appears to be funded through private investment to support its research programs into Alzheimer's, Parkinson's, and depression.

Go-to-market motion1 record

Core offering

NeuroClin Glasgow is a medical research centre and laboratory that conducts clinical research into Alzheimer's disease, Parkinson's disease, and depression. It operates as a neurological research organization headquartered in Scotland with approximately 60 employees following expansion supported by investment from N4 Partners. The company has launched dedicated research programs including a Parkinson's research program as part of its growth.

Product overview

NeuroClin Glasgow is a neurological research organization based in Scotland that focuses on research into neurological conditions including Alzheimer's disease, Parkinson's disease, and depression. The company operates from expanded headquarters and employs approximately 60 staff members. No specific named products, modules, or commercial service offerings are described in the available source material.

Differentiator

Problem solved

Functional benefit

Products and services

• Alzheimer's disease clinical research programme Clinical research program targeting Alzheimer's disease, conducted from NeuroClin's Scottish laboratory for healthcare institutions, medical research organisations, and pharmaceutical partners advancing neurological treatments.
• Parkinson's disease clinical research programme Clinical research program targeting Parkinson's disease, launched following N4 Partners' seven-figure investment and supporting the organisation's expanded neurological research portfolio for pharmaceutical and academic partners.
• Depression clinical research programme Clinical research program targeting depression, conducted from NeuroClin's Scottish laboratory for healthcare institutions, medical research organisations, and pharmaceutical partners working on mental health treatments.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Medpace: Medpace is a mid-to-large CRO running global clinical trials across therapeutic areas including neurology; comparable as a broader incumbent with neuroscience research capabilities similar in function to NeuroClin's CNS research focus.
• IQVIA: IQVIA is a global CRO and clinical research services giant with broad CNS capability; comparable as a large incumbent that delivers clinical research at a scale and geographic reach NeuroClin aspires to.
• Charles River Laboratories: Charles River is a large, established CRO with discovery and preclinical research services spanning multiple therapeutic areas including CNS; comparable as a much larger incumbent offering the same category of outsourced research services NeuroClin provides.

Emerging players

• Prothena: Prothena is a clinical-stage biotech focused on protein-misfolding diseases including Parkinson's disease, comparable to NeuroClin's neurodegenerative research scope.
• Evotec: Evotec is a European drug discovery and development platform with significant CNS/neuroscience partnerships; comparable as an emerging R&D player operating at the intersection of biotech and CRO services in the same therapeutic areas.
• Alector: Alector is an emerging biotech developing therapeutics for Alzheimer's disease and other neurodegenerative disorders; overlaps with NeuroClin's Alzheimer's and broader neurodegeneration research focus.
• Denali Therapeutics: Denali is a clinical-stage biotech focused on neurodegeneration — particularly Parkinson's and Alzheimer's — making it a directly comparable emerging player pursuing the same therapeutic indications NeuroClin researches.
• Sage Therapeutics: Sage Therapeutics develops CNS therapeutics with a historical focus on depression and neurology; overlaps directly with NeuroClin's depression and broader neurological research program.

Direct peers

• Biotrial: Biotrial is a European-based clinical research organization with a strong neuroscience specialty, conducting early-phase clinical trials in neurological and psychiatric indications — directly comparable to NeuroClin Glasgow's clinical research focus on Alzheimer's, Parkinson's, and depression.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size CRO with a CNS/neuroscience center of excellence that runs clinical research programs across neurodegenerative and psychiatric conditions, comparable in scope and therapeutic focus to NeuroClin Glasgow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/NeuroClinGLA

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroClin Glasgow